Cancer drug delivery最新文献_第7页

An approach to the therapy of metastases from cancer of the upper rectum: a working hypothesis. 一种治疗上直肠癌转移的方法:一个有效的假设。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.19

L Weiss, E Mayhew

{"title":"An approach to the therapy of metastases from cancer of the upper rectum: a working hypothesis.","authors":"L Weiss, E Mayhew","doi":"10.1089/cdd.1985.2.19","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.19","url":null,"abstract":"Previously reported analyses of autopsy data gathered from patients dying from the sequelae of adenocarcinomas of the upper rectum revealed a step-wise sequence in the development of distant metastases. First, dissemination via the portal vein led to secondary hepatic metastases. Cancer cells from these liver metastases (not the primary cancer) disseminated via the inferior vena cava to generate tertiary pulmonary metastases. Cancer cells from the lung metastases (not the primary or secondary cancers) then disseminated via the arterial route to give rise to metastases in other organs. We propose a protocol for the treatment of patients with upper rectal carcinomas, based on the expectation that, at different times after diagnosis, some patients will have no distant metastases, metastases in the liver only, or in the liver and lungs only. The protocol for therapy is based on currently available liposome technology, by means of which high doses of drugs can be targeted to the liver and lungs containing the metastases, yet distinct from the metastases. It is argued that selective local delivery of this type would increase the dose of cytotoxic agent delivered, thereby increasing the chances of overcoming the relative drug-resistance of the metastatic cancer cells and, at the same time, reduce the risk of nonspecific toxicity. Liver and lung-selective liposomes could, when necessary, be delivered at the same time, in the same systemic venous infusion.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 1","pages":"19-33"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15164416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Factors that affect antiferritin localization in four rat hepatoma models. 四种大鼠肝癌模型中影响抗铁蛋白定位的因素

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.139

R A Rostock, K A Kopher, T W Bauer, J L Klein

{"title":"Factors that affect antiferritin localization in four rat hepatoma models.","authors":"R A Rostock, K A Kopher, T W Bauer, J L Klein","doi":"10.1089/cdd.1985.2.139","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.139","url":null,"abstract":"The effect of tumor size, vascularity, ferritin content and the amount of injected 131I-antiferritin on tumor localization was studied in four hepatoma models with varying growth rates, histology, vascularity, and ferritin content. Separate groups of 12 animals with the H-4-II-E, 7800, 7777, and 3924A rat hepatomas with less than 2 g or greater than 2 g tumors were injected with escalating doses of 131I-antiferritin or 131I nonspecific IgG (control). Tumor vascularity was measured by 51Cr-labeled erythrocyte injection, ferritin content of tumors by radioimmunoassay and immunoperoxidase staining, and the histological location of 131I-antiferritin by autoradiography. 131I-antiferritin specifically localized in the H-4-II-E and 7800 models and correlated with the tumor size, vascular content, and amount of injected antiferritin. No localization took place in the 7777 or 3924A tumors despite the presence of ferritin in these models. The only factor that correlated with localization in the models was vascularity. The vascularity of 3924A and 7777 tumors was significantly reduced in comparison to the H-4-II-E and 7800 tumors. The dependence of targeting on vascularity was demonstrated with autoradiography as well. These findings indicate the correlation of vascularity and tumor localization with 131I-antiferritin.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"139-45"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15016840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Intrapericardial instillation of cisplatin in a patient with a large malignant effusion. 顺铂在大量恶性积液患者心包内灌注。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.49

M Markman, S B Howell

引用次数: 20

Hepatic arterial and systemic chemotherapy for the treatment of primary and secondary malignancies of the liver. 肝动脉和全身化疗用于治疗原发性和继发性肝脏恶性肿瘤。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.119

C B Vaughn, J Chapman, J Zaks, S Young, B Chinn, K Enochs, E Maniscalco, H Duffin, G Groshko, S Reznik

{"title":"Hepatic arterial and systemic chemotherapy for the treatment of primary and secondary malignancies of the liver.","authors":"C B Vaughn, J Chapman, J Zaks, S Young, B Chinn, K Enochs, E Maniscalco, H Duffin, G Groshko, S Reznik","doi":"10.1089/cdd.1985.2.119","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.119","url":null,"abstract":"Twenty-two patients with metastatic and primary cancer of the liver were treated with 5-fluoro-2'-deoxyuridine (5FUDR), Mitomycin C (Mito C), and 1 (-2-chlorethyl)-4(methyl-cyclohexyl)-1-nitrosourea (MeCCNU). 5FUDR 0.3 mg/kg/day was administered as a continuous infusion via the hepatic artery. Mito C (10 mg/M2) and MeCCNU (50 mg/M2) were given I.V. and orally, respectively, every 8 weeks. Remission of the neoplastic lesions within the liver was seen in 10 patients (4CR, 6PR). Five patients had stabilization of their lesion neoplasm for at least 4 months. The response rate in this study was 6/15 (40%) in patients with colon cancer metastatic to the liver. Toxicity was mainly hematologic and hepatic. Three patients experienced a platelet count below 25,000 and/or white blood count below 1000. Fifteen patients had hepatic toxicity showing elevation in SGOT and SGPT. The SGOT and SGPT returned to normal when the 5FUDR was discontinued. The combination of 5FUDR intraarterially, and Mito C and MeCCNU systemically, demonstrated activity in malignancies of the liver. This study proved that chemotherapy can be administered systemically and regionally with acceptable toxicity.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"119-26"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14067606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol. 大剂量甲氨蝶呤输注的剂量预测。第一部分:经典试验剂量方案的评价。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.271

J P Cano, R Bruno, N Lena, R Favre, A Iliadis, A M Imbert

{"title":"Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.","authors":"J P Cano, R Bruno, N Lena, R Favre, A Iliadis, A M Imbert","doi":"10.1089/cdd.1985.2.271","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.271","url":null,"abstract":"A preliminary methotrexate (MTX) kinetic evaluation following administration of an IV bolus (test-dose) allowed individualization of high-dose infusions (HD-MTX). This approach combined with therapeutic drug monitoring was found to have good performance over a large scale of predicted steady-state levels (Css) (10(-5) to 10(-4) M over 24 to 36 h) corresponding to 17 to 650 mg/h deliveries (root mean squared error : rmse (precision) = 1.54 X 10(-5) M (21.4%) and mean error : me (bias) = 0.043 X 10(-5) M (NS)). However a significative (p less than 0.05) but rather low over-estimation of dosage (me = 7.38 X 10(-5) M (14.8%)) associated to a decrease in the prediction precision (rmse = 13.3 X 10(-5) M (26.6%)) occurred in 5 X 10(-4) M predicted Css over 8 h (970 to 1970 mg/h deliveries). However in a number of cases (6 out of 29) important deviations from predicted Css occurred, implying the need to stop the infusion before 8 h. These results indicated that MTX pharmacokinetics was linear from low test-dose bolus injections to high-dose infusions. This allowed dosage predictions based upon preliminary estimation of MTX clearance and associated to therapeutic drug monitoring during and following infusion.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"271-6"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14979368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Immunomodulatory activity of human leukocyte interferon in cancer patients: results obtained during pulse therapy schedule. 肿瘤患者白细胞干扰素的免疫调节活性:在脉冲治疗方案中获得的结果。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.91

R D Medenica, N Slack

{"title":"Immunomodulatory activity of human leukocyte interferon in cancer patients: results obtained during pulse therapy schedule.","authors":"R D Medenica, N Slack","doi":"10.1089/cdd.1985.2.91","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.91","url":null,"abstract":"We evaluated and previously reported the efficacy of alpha-interferon (alpha-IFN) in 84 cancer patients (19). IFN was administered in a pulse fashion given for 3 consecutive days every 4 weeks. We also evaluated the immunomodulatory effect of IFN which constitutes the basis for the current report. Before, during and after courses of IFN treatment, the immune status of the patients was assessed by: (i) circulating immune complexes, (ii) change in lymphocyte type including (a) natural killer (NK) cells, (b) T-cell subsets (suppressor, helper) and (c) HLA-Dr antigen positivity, (iii) myelopoietic differentiation, (iv) macrophage-dependent tumor cytotoxicity with measurements of macrophage-derived growth factor (MDGF), (v) granulocyte functions, (vi) antibody formation against IFN, and (vii) antiproliferative activity of IFN. In addition, LDH, beta-2 microglobulin, and CEA as tumor markers were obtained. High serum or plasma IFN levels were associated with increased activity of T suppressor cells, increased HLA-Dr antigen, and increased NK activity. The increase of these three parameters was directly related to tumor response. In vitro inhibition of tumor cells in tissue culture by IFN culture was predictive of objective tumor response in those patients whose tumor cells were tested. In addition, IFN induced release of MDGF by monocytes. It is apparent that in addition to direct antitumor effect, IFN has multiple modulatory effects on the immune system in man that may aid in tumor control when given in a pulse schedule.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"91-118"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.91","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14993854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Cancer chemotherapy: alternative routes of drug administration. A review. 癌症化疗:替代给药途径。复习一下。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.147

H J Keizer, H M Pinedo

{"title":"Cancer chemotherapy: alternative routes of drug administration. A review.","authors":"H J Keizer, H M Pinedo","doi":"10.1089/cdd.1985.2.147","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.147","url":null,"abstract":"This review covers recent developments in regional cancer chemotherapy, including the pharmacological background, technical progress, and clinical experience. Intrathecal chemotherapy is an approach that has acquired an established place, although its ultimate potentials are not known yet. The therapeutic value of hepatic intraarterial drug infusion is still unclear, although this route has been used for more than 20 years. Furthermore, the evaluation of alternative routes via the pleural and peritoneal cavities and other arteries is still in an experimental phase. Interest in these treatment modalities has been stimulated by a number of recent developments in separate fields. Major technical advances have been made, including surgically placed and totally implantable elastic catheters and subcutaneous portals and pumps. In addition, a pharmacokinetic model describing the fate of drugs administered via an artery or cavity has been developed. These developments have made it possible not only to design randomized studies and treat a larger number of patients in a relatively short time with reduced morbidity, but also to improve greatly the selection of drugs, target organs, and administration schedules. Ongoing clinical studies can be expected to lead to improved treatment results as well as provide data on dose-response relationships and drug schedule dependency for specific tumor types.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"147-69"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15016841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Enhanced antitumor effects with intralymphatic delivery using bacillus Calmette-Guerin in animal models. 卡介苗芽孢杆菌在动物模型中淋巴内给药增强抗肿瘤作用。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.127

K A Jeglum, C Mangan, J E Wheeler

引用次数: 6

Pilot study of intra-arterial floxuridine, mitomycin and doxorubicin in combination with degradable starch microspheres to treat primary and metastatic tumors of the liver. 动脉内氟尿定、丝裂霉素和阿霉素联合可降解淀粉微球治疗原发性和转移性肝脏肿瘤的初步研究。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.305

C E Pfeifle, S B Howell, J J Bookstein

引用次数: 5

An evaluation of the effects of combination chemotherapy in vitro using DNA-reactive agents. 体外应用dna活性药物联合化疗的疗效评价。

Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.255

K Pavelic, T A Beerman, R J Bernacki

{"title":"An evaluation of the effects of combination chemotherapy in vitro using DNA-reactive agents.","authors":"K Pavelic, T A Beerman, R J Bernacki","doi":"10.1089/cdd.1985.2.255","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.255","url":null,"abstract":"The combined application of DNA unwinding and strand-scission agents is a novel and potentially important approach to cancer therapy, based in part on mechanistic considerations of drug action. In order to evaluate this hypothesis a number of experiments were performed in which the cellular cytotoxicity of DNA reactive agents (ethidium bromide, adriamycin or cis-platinum) were evaluated alone and in combination with bleomycin, a strand-scission agent, using a number of different tumor cell systems in vitro. The results of these studies indicated that combinations of these agents were found to be much more effective than treatment with single drugs alone. This conclusion was warranted for the action of ethidium bromide followed by bleomycin with murine L1210 leukemia, melanoma B16-BL6 and human HeLa cells, and cis-platinum followed by bleomycin with L1210 and B16-BL6 cells. These data support previous findings in which synergistic growth inhibition of L1210 cells by ethidium bromide, followed by bleomycin was explained by a two-step mechanism; first, ethidium bromide introduces changes in DNA-conformation resulting in the facilitation of a second step in which bleomycin cleaves DNA more efficiently. Therefore, the rational use of combinations of DNA reactive agents based on mechanistic considerations should result with improved therapeutic regimens for the treatment of cancer.","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"255-70"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13562460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4